State Key Laboratory of Oncology in Southern China, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Department of Radiation Oncology, Guangzhou, China.
State Key Laboratory of Oncology in Southern China, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Imaging Diagnosis and Interventional Center, Guangzhou, China.
Sci Rep. 2017 Feb 17;7:42624. doi: 10.1038/srep42624.
The effectiveness of neoadjuvant chemotherapy (NACT) followed by concurrent chemoradiotherapy (CCRT) compared with CCRT alone in nasopharyngeal carcinoma (NPC) patients who presented with cervical nodal necrosis (CNN) is unknown. A total of 792 patients with stage T1-4N1-3M0 NPC and presented with CNN based on magnetic resonance imaging were retrospectively reviewed. Propensity score matching method was used to balance treatment arms for baseline characteristics. Eventually, 508 patients were propensity-matched on a 1:1 basis to create two groups (NACT + CCRT and CCRT groups). Survival rates were calculated by Kaplan-Meier method and differences were compared by using the log-rank test. The 5-year disease specific survival, disease-free survival and distant metastasis-free survival were significantly higher in NACT + CCRT group relative to the matched CCRT group (82.1% vs. 72.5%, P = 0.021; 70.3% vs. 54.1%, P < 0.001; 81.9% vs. 67.3%, P < 0.001, respectively). Although the rates of grade 3-4 leucopenia and mucositis were higher in NACT + CCRT group than CCRT group, compliance with the combined treatment was good and no significant difference was observed between two groups. NACT followed by CCRT was relatively safe and could achieve better survival than CCRT alone in NPC patients with CNN by reducing the risk of death, tumor progression and distant metastasis.
新辅助化疗(NACT)联合同期放化疗(CCRT)对比单纯 CCRT 治疗伴有颈部淋巴结坏死(CNN)的鼻咽癌(NPC)患者的疗效尚不清楚。本研究回顾性分析了 792 例基于磁共振成像诊断为 T1-4N1-3M0 期伴有 CNN 的 NPC 患者。采用倾向性评分匹配法平衡治疗组的基线特征。最终,按 1:1 比例对 508 例患者进行倾向性评分匹配,分为 NACT+CCRT 组和 CCRT 组。采用 Kaplan-Meier 法计算生存率,并用对数秩检验比较差异。NACT+CCRT 组的 5 年疾病特异性生存率、无病生存率和无远处转移生存率明显高于 CCRT 组(82.1% vs. 72.5%,P=0.021;70.3% vs. 54.1%,P<0.001;81.9% vs. 67.3%,P<0.001)。尽管 NACT+CCRT 组的 3-4 级白细胞减少和黏膜炎发生率高于 CCRT 组,但联合治疗的依从性良好,两组间无显著差异。NACT 联合 CCRT 治疗伴有 CNN 的 NPC 患者相对安全,可降低死亡、肿瘤进展和远处转移风险,从而获得比单纯 CCRT 更好的生存。